Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.

Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO.

PLoS One. 2013 Aug 13;8(8):e72609. doi: 10.1371/journal.pone.0072609. eCollection 2013.

2.

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.

Int J Oncol. 2015 Feb;46(2):607-18. doi: 10.3892/ijo.2014.2747. Epub 2014 Nov 11.

3.

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.

J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.

4.

SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.

Kolukula VK, Sahu G, Wellstein A, Rodriguez OC, Preet A, Iacobazzi V, D'Orazi G, Albanese C, Palmieri F, Avantaggiati ML.

Oncotarget. 2014 Mar 15;5(5):1212-25.

5.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

6.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
7.

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.

Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S.

Oncotarget. 2015 Jul 30;6(21):18641-52.

8.

p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.

Malisic E, Jankovic R, Slavkovic D, Milovic-Kovacevic M, Radulovic S.

J BUON. 2010 Jan-Mar;15(1):101-6.

PMID:
20414935
9.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

10.

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.

Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, Wang TL, Shih IM.

Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. Epub 2007 Aug 10.

PMID:
17692090
11.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS).

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

12.

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP.

Hum Cell. 2017 Jul;30(3):226-236. doi: 10.1007/s13577-017-0162-1. Epub 2017 Mar 1.

PMID:
28251557
13.

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S.

Gynecol Oncol. 2015 Jul;138(1):159-64. doi: 10.1016/j.ygyno.2015.04.039. Epub 2015 May 6.

14.
15.

TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.

Zhang M, Zhuang G, Sun X, Shen Y, Wang W, Li Q, Di W.

Diagn Pathol. 2017 Feb 2;12(1):16. doi: 10.1186/s13000-017-0605-8.

16.

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.

Mota A, Triviño JC, Rojo-Sebastian A, Martínez-Ramírez Á, Chiva L, González-Martín A, Garcia JF, Garcia-Sanz P, Moreno-Bueno G.

BMC Cancer. 2015 Nov 30;15:940. doi: 10.1186/s12885-015-1952-z.

17.

p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.

Laframboise S, Chapman W, McLaughlin J, Andrulis IL.

Cancer J. 2000 Sep-Oct;6(5):302-8.

PMID:
11079169
18.

The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN.

PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20.

19.

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF.

Clin Cancer Res. 2001 Oct;7(10):2984-97.

20.

Distant metastases in ovarian cancer: association with p53 mutations.

Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE.

Clin Cancer Res. 1999 Sep;5(9):2485-90.

Supplemental Content

Support Center